Posts by Rebecca Suk Heist, MD, MPH
-
Study Provides Insight Into Overcoming Acquired Resistance to KRAS-G12C Inhibitors
Researchers at the Massachusetts General Hospital Cancer Center and colleagues have identified mutations that make lung cancer resistant to adagrasib and other KRAS-G12C inhibitors. Their findings provide clues to designing next-generation inhibitors and combination regimens.
-
Capmatinib Benefits Adults with Advanced NSCLC and MET Exon 14 Skipping Mutation
Rebecca S. Heist, MD, MPH, and colleagues led the phase 2 GEOMETRY mono-1 trial, the basis for FDA approval of capmatinib, a highly specific new MET inhibitor for treatment of adults with MET exon 14–mutated metastatic non–small-cell lung cancer.
Biography
Physician in the Division of Hematology/Oncology, Mass General Cancer Center
Mass General Cancer Center
An integral part of one of the world’s most distinguished academic medical centers, the Massachusetts General Hospital Cancer Center is among the leading cancer care providers in the United States.
